Abstracts tagged "Biologic agents"

Abstract Number: 1359 • 2014 ACR/ARHP Annual Meeting
Care of Women with Rheumatological Conditions during Family Planning and Pregnancy
Megan E. B. Clowse¹, Munther Khamashta², Daphnee S. Pushparajah³ and Eliza Chakravarty⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ³UCB Pharma, Brussels, Belgium, ⁴OMRF, Oklahoma City, OK
Background/Purpose Rheumatological diseases often affect women of reproductive age and can impact pregnancy outcomes. There is a need to understand how patients (pts) are managed…
Abstract Number: 135 • 2014 ACR/ARHP Annual Meeting
Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents
Asami Abe¹, Hajime Ishikawa¹ and Akira Murasawa², ¹Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Niigata Rheumatic Center, Shibata, Japan
Background/Purpose: An early diagnosis and tight disease control have increased in importance in the era of biological therapy for rheumatoid arthritis (RA). Ultrasonography (US) of…
Abstract Number: 2926 • 2014 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Virginia Ruiz-Esquide¹, Azucena González Navarro², Jordi Yagüe³, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Calprotectin is a major S100 leucocyte protein, is associated to disease activity in rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients. Calprotectin is a potentially…
Abstract Number: 2204 • 2014 ACR/ARHP Annual Meeting
New Onset Vitiligo Under Biological Agents: A Case Series
Laure Mery-Bossard¹, Emmanuelle Mahé², Guillaume Charby³, François Maccari⁴, Nathalie Quilès⁵, Ziad Reguiai⁶, Abdallah Khemis⁷, Anne Grasland⁸, Morgane Guerin⁹, Denis Jullien¹⁰, Kelly Bagny¹¹, Jean Sibilia¹², Eric Toussirot^13,14 and Resopso Le CRI¹⁵, ¹Dermatology, Centre hospitalier, Mantes la Jolie, France, ²Dermatology, Centre hospitalier, Argenteuil, France, ³Dermatology, University hospital, Amiens, France, ⁴Dermatology, Centre hospitalier, Saint Mandé, France, ⁵Dermatology, University hospital, Marseille, France, ⁶Dermatology, Uniersity hospital, Reims, France, ⁷Dermatology, University hospital, Nice, France, ⁸Internal medicine, University hospital, Colombe, France, ⁹Dermatology, University hospital, Lyon, France, ¹⁰Pavillon r dermatologie, Hopital Edouard Herriot, Lyon, France, ¹¹Rheumatology, University hospital, La Réunion, France, ¹²Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹³Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ¹⁴Rheumatology, University hospital, Besançon, France, ¹⁵University Hospital, Paris, France
Background/Purpose: biological agents are now widely used in clinical practice for the treatment of chronic cutaneous, rheumatic and gastro-intestinal inflammatory diseases. Various cutaneous lesions have…
Abstract Number: 1159 • 2014 ACR/ARHP Annual Meeting
Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic
Liliana Sedova^1,2, Monika Urbanova³, Jiri Stolfa^2,3, David Suchy⁴, Andrea Smrzova⁵, Tomas Mlcoch⁶, Jiri Klimes⁷ and Tomas Dolezal⁷, ¹rheumatology, Institute of Rheumatology, Prague, Czech Republic, ²Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, ³Inpatients´ Clinic, Institute of Rheumatology Prague, Prague, Czech Republic, ⁴Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, ⁵3rd internal clinic, University hospital Olomouc, Olomouc, Czech Republic, ⁶Institute of Health Economics and Technology Assessment, Prague, Dominica, ⁷Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic
Background/Purpose To describe the quality-of-life (QoL), productivity impairment, clinical indicators and health care costs in relationship to functional status described by Bath Ankylosing Spondylitis Functional…
Abstract Number: 114 • 2014 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists
John J. Cush¹ and Jeffrey R. Curtis², ¹Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ²University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Changes in US rheumatologic practice for rheumatoid arthritis (RA) patients in the past decade have been influenced by novel therapies, increasing disease metric use…
Abstract Number: 2873 • 2014 ACR/ARHP Annual Meeting
Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Alison Maloney¹, Drew Hotson², Stephen Rapecki¹, Gianluca Fossati¹, Simon Lumb¹, David Rosen², Santosh Putta², Nikil Wale², David Spellmeyer², Alessandra Cesano², Rachael Hawtin² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Nodality Inc., South San Francisco, CA
Background/Purpose Epratuzumab is a humanized monoclonal antibody targeting the B cell-specific protein CD22 and is in Phase 3 clinical trials in patients with systemic lupus…
Abstract Number: 2152 • 2014 ACR/ARHP Annual Meeting
Frequency of Postoperative Deep Infection in Patients with Rheumatoid Arthritis
Masayuki Azukizawa and Hiromu Ito, Orthopaedic surgery, Kyoto University, Kyoto, Japan
Background/Purpose: Rheumatoid arthritis (RA) is known to be associated with an increased risk of serious infection. It has been discussed about the risk of the…
Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Christian Gissel¹, Georg Götz², Holger Repp³ and Uwe Lange⁴, ¹Rheumatology, Justus-Liebig-University Giessen, Giessen, Germany, ²Department of Economics and Business, Justus-Liebig-University Giessen, Giessen, Germany, ³Department of Medicine, Justus-Liebig-University Giessen, Giessen, Germany, ⁴Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…
Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Munther Khamashta^1,2, Joan T. Merrill³, Victoria P. Werth^4,5, Richard Furie⁶, Kenneth Kalunian⁷, Gabor G. Illei⁸, Jorn Drappa⁸, Liangwei Wang⁸ and Warren Greth⁸, ¹Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, ²Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Philadelphia VA Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶North Shore-LIJ Health System, Lake Success, NY, ⁷UCSD School of Medicine, La Jolla, CA, ⁸MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
Abstract Number: 2815 • 2014 ACR/ARHP Annual Meeting
Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
T. Martijn Kuijper¹, J.J. Luime¹, P.H.P. de Jong², A. H. Gerards³, D. van Zeben⁴, I. Tchetverikov⁵, P.B.J. de Sonnaville⁶, M. van Krugten⁷, B. Grillet⁸, J.M.W. Hazes⁹ and A.E.a.M. Weel^10,11, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁷Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁸Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹⁰Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ¹¹Rheumatology, MD, PhD, Rotterdam, Netherlands
Background/Purpose: To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to…
Abstract Number: 2154 • 2014 ACR/ARHP Annual Meeting
Risk for Developing Adult T-Cell Leukemia in Patients with Human T Lymphotropic Virus Type-I Carrier Receiving Immunosuppressive Therapy
Kensuke Nakanishi¹, Rita Mcgill² and Mitsuyo Kinjo¹, ¹Internal Medicine, Okinawa Chubu Hospital, Uruma City Okinawa, Japan, ²Nephrology, AGH Nephrology Associates, Pittsburgh, PA
Background/Purpose: Human T-lymphotropic virus type-I (HTLV-1) is a retrovirus associated with Adult T-cell leukemia (ATL) that is commonly seen in endemic areas. Several case reports…
Abstract Number: 921 • 2014 ACR/ARHP Annual Meeting
Comparison of Infection Rates in Patients Receiving Denosumab, Denosumab and Biologics and Biologics Alone in a Suburban Rheumatology Clinic
Sajina Prabhakaran¹ and Charles Pritchard², ¹Drexel Rheumatology, Drexel University College of Medicine, Philadelphia, PA, ²Drexel University College of Medicine, Willow Grove, PA
Background/Purpose: Biologics including rituximab, abatacept and belimumab increase the risk of infection in patients. Denosumab, a RANK-ligand inhibitor used in the treatment of osteoporosis may…
Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting
Variation in the Prescribing Practices of Biologic Dmards
Heather O. Tory¹, Josephine A. Awosogba², Amish J. Dave², Jonathan S. Coblyn², Daniel H. Solomon² and Sonali P. Desai², ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].